lung cancer
Conditions
Interventions
treatment group:IBI308 combined with chemotherapy
Sponsors
Henan Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Non-small cell lung cancer confirmed by cytology or histology with PD-L1 = 1% of patients; 2. The patient's TNM stage was IB-IIIA (8th edition lung cancer TNM stage); 3. The investigator confirmed at least one measurable lesion according to the RECIST 1.1 standard; 4. ECOG PS score is 0 ~ 2; 5. Aged 18-70 years; 6. Expected survival period > three months; 7. Subjects had no major organ dysfunction: blood routine: white blood cells = 4.0 × 10^9 / L, neutrophils = 2.0 × 10^9 / L, platelet count = 100 × 10^9 / L, hemoglobin = 95g / L; liver function: Serum bilirubin was less than 1.5 times the maximum normal value; ALT and AST were less than 1.5 times the maximum normal value; renal function: creatinine clearance was =45 mL/min; cardiac function: basically normal. 8. He has not received any systematic anti-tumor treatment for advanced disease; 9. The patient has good compliance with the treatment and follow-up, can understand the situation of the study and sign the informed consent form. 10. Patients confirmed by histological specimens not eligible for EGFR or ALK targeted therapy (documented evidence of no tumor EGFR-sensitive mutations and no ALK gene rearrangement).
Exclusion criteria
Exclusion criteria: 1. Any unstable systemic disease (including active infection, grade 4 hypertension, unstable angina, congestive heart failure, liver, kidney or metabolic disease); 2. Pregnant or lactating women; 3. Patients with a history of mental illness that is difficult to control; 4. Patients with allergies and allergies known or suspected to be allergic to any study drug; 5. Systemic treatment required within 2 years prior to first dose Active autoimmune diseases (eg, using a disease-modifying drug, a corticosteroid, or an immunosuppressive agent). Alternative therapies (such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic treatments; 6. Patients with poor adherence; 7. Researchers believe that it is not appropriate to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| major pathological response; | — |
Countries
China
Contacts
Public ContactYanqiu Zhao
Henan Cancer Hospital
Outcome results
None listed